HUE026779T2 - Nagy érzékenységû, több paraméteres eljárás ritkán elõforduló esemény elemzésére biológiai mintában - Google Patents

Nagy érzékenységû, több paraméteres eljárás ritkán elõforduló esemény elemzésére biológiai mintában Download PDF

Info

Publication number
HUE026779T2
HUE026779T2 HUE09251888A HUE09251888A HUE026779T2 HU E026779 T2 HUE026779 T2 HU E026779T2 HU E09251888 A HUE09251888 A HU E09251888A HU E09251888 A HUE09251888 A HU E09251888A HU E026779 T2 HUE026779 T2 HU E026779T2
Authority
HU
Hungary
Prior art keywords
cells
circulating
sample
interest
cartridge
Prior art date
Application number
HUE09251888A
Other languages
English (en)
Inventor
Mark Carle Connelly
Frank Coumans
Steven Gross
James Michael Kelly
Original Assignee
Janssen Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41611032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE026779(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Diagnostics Llc filed Critical Janssen Diagnostics Llc
Publication of HUE026779T2 publication Critical patent/HUE026779T2/hu

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6428Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/645Specially adapted constructive features of fluorimeters
    • G01N21/6456Spatial resolved fluorescence measurements; Imaging
    • G01N21/6458Fluorescence microscopy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6428Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G01N2021/6441Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks with two or more labels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Optics & Photonics (AREA)
  • Ecology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Claims (2)

Szabadalmi igénypontok
1, Eljárás az érzékenység növelésére ritkán elö&rdnló esemény elemzésében, amely magában foglalja aibvetkegSket: a. minta eiMIMtása ÎÎKïreszæens jelöléssel, b. a misia szfeinnelése, ezáltal eéleseroények azonosítása, ahol a eéíesemény a következekből állő csoportból van ki választva: keringő epiíéísej tefc, keringő iumorsojíek, keringő endotéisejték, ieukoeitak, Hmfixnta-alcsoportok, adott sspszervssskéí vagy receptort tartalmazó sejtek, sejjtömselék, rooősoi sejtek és törmelékük vagy az előzőek kombi náclói, c. folyadék leszívása a minidről, ezáltal a eéksseményéfc azonos bolyért: tartása. d. a célesemények tőtohalványítása, e. a eéíesemény újrafestése szekunder módon fluoreszcensen jelölt markend, ahol a szekunder módon jelölt tómkor fjuoíeszdeós elkmartvag-konjugátum vagy fluoreszcens ellenanyag-konjugátum és fest# komhmdoiftja, f. a célesemények újraszkenneiése, és g. a c-f lépések ismétlése valamennyi további
2. Az 1. igénypont szerinti eljárás, aboi a celesemény keringő tumorsejt. % .Az t, igénypont szerinti efjÉés, ..ahol egy további lépés a eélesemény maitiparaméteres genotipus-protil-nieghatározíísa. 4. Ä 3. igénypont szerinti eljárás, aboi a genotipusproiil-ísegbatározás FISH.
HUE09251888A 2008-07-29 2009-07-28 Nagy érzékenységû, több paraméteres eljárás ritkán elõforduló esemény elemzésére biológiai mintában HUE026779T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/181,399 US9134237B2 (en) 2005-09-20 2008-07-29 High sensitivity multiparameter method for rare event analysis in a biological sample

Publications (1)

Publication Number Publication Date
HUE026779T2 true HUE026779T2 (hu) 2016-07-28

Family

ID=41611032

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09251888A HUE026779T2 (hu) 2008-07-29 2009-07-28 Nagy érzékenységû, több paraméteres eljárás ritkán elõforduló esemény elemzésére biológiai mintában

Country Status (15)

Country Link
US (1) US9134237B2 (hu)
EP (1) EP2169387B1 (hu)
JP (1) JP6109464B2 (hu)
KR (2) KR101764597B1 (hu)
CN (1) CN101672779B (hu)
BR (2) BRPI0902559A2 (hu)
CA (2) CA2674187C (hu)
DK (1) DK2169387T3 (hu)
ES (1) ES2542061T3 (hu)
HK (1) HK1140820A1 (hu)
HU (1) HUE026779T2 (hu)
IL (1) IL199798A (hu)
MX (1) MX2009008060A (hu)
PL (1) PL2169387T3 (hu)
PT (1) PT2169387E (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127302B2 (en) 2005-09-20 2015-09-08 Janssen Diagnostics, Llc System for the detection and enumeration of suspect target cells in a mixed cell population
US20120276555A1 (en) 2009-10-21 2012-11-01 Peter Kuhn Method of Using Non-Rare Cells to Detect Rare Cells
US10047398B2 (en) 2010-10-06 2018-08-14 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
US10114020B2 (en) 2010-10-11 2018-10-30 Mbio Diagnostics, Inc. System and device for analyzing a fluidic sample
WO2013031365A1 (ja) * 2011-08-30 2013-03-07 オリンパス株式会社 標的粒子の検出方法
WO2013072571A1 (fr) * 2011-11-17 2013-05-23 Institut Gustave Roussy Methode de caracterisation de cellules tumorales circulantes et application au diagnostic
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
JP6386450B2 (ja) 2012-06-06 2018-09-05 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ(イエレベ、バルセロナ)Fundacio Institut De Recerca Biomedica (Irb Barcelona) 肺がん転移の診断、予後診断および処置のための方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20140105918A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US9739714B2 (en) 2012-10-29 2017-08-22 Mbio Diagnostics, Inc. Particle identification system, cartridge and associated methods
EA201691496A1 (ru) 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
EP3108246B1 (en) * 2014-02-21 2019-10-09 Epic Sciences, Inc. Methods for analyzing rare circulating cells
EP3186397B1 (en) * 2014-08-25 2024-02-07 Creatv Microtech, Inc. Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
US10793642B2 (en) 2014-12-11 2020-10-06 Inbiomotion S.L. Binding members for human c-MAF
US10078778B2 (en) * 2015-01-15 2018-09-18 Massachusetts Institute Of Technology Systems, methods, and apparatus for in vitro single-cell identification and recovery
GB201507202D0 (en) 2015-04-28 2015-06-10 Stfc Science & Technology Receptor tyosine kinase biomarkers
CN108474025A (zh) * 2016-01-07 2018-08-31 克里维提夫微技术公司 采用依次荧光淬灭和重新染色的生物样品的多表型分型
PT3458610T (pt) 2016-05-25 2021-06-29 Inbiomotion Sl Tratamento terapêutico de cancro da mama baseado no estado de c-maf
US11353400B2 (en) * 2016-07-19 2022-06-07 Altius Institute For Biomedical Sciences Methods for fluorescence imaging microscopy and Nano-FISH
CN111565725A (zh) 2017-11-22 2020-08-21 生物运动有限公司 基于c-maf状态的乳腺癌的治疗性处理
CN111330311B (zh) * 2020-02-13 2021-02-23 浙江大学 一种相变诱导靶标富集的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578444A (en) 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
WO1995031481A1 (en) * 1994-05-18 1995-11-23 The Research And Development Institute, Inc. Simple, rapid method for the detection, identification and enumeration of specific viable microorganisms
EP0760008A1 (en) 1994-05-19 1997-03-05 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
WO1997038313A1 (en) 1996-04-05 1997-10-16 The Johns Hopkins University A method of enriching rare cells
DE19709348C2 (de) 1996-05-29 1999-07-01 Schubert Walter Dr Md Automatisches Multi-Epitop-Ligand-Kartierungsverfahren
GB9716664D0 (en) 1997-08-06 1997-10-15 Norwegian Inst Of Fisheries & A method of removing nucleic acid contamination reactions
WO1999041613A1 (en) 1998-02-12 1999-08-19 Immunivest Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
JP2002517183A (ja) 1998-06-02 2002-06-18 イェール ユニバーシティ マルチパラメトリック蛍光in−situハイブリッド形成法
US6429293B1 (en) 1998-06-26 2002-08-06 Hsc Research And Development Limited Partnership Sculpin-type antifreeze polypeptides and nucleic acids
AU2876900A (en) 1999-02-10 2000-08-29 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids andmethods of use
AU6350800A (en) 1999-07-19 2001-02-05 American Laboratory Technologies, Inc. Removing repetitive sequences from dna
US6203992B1 (en) 1999-10-15 2001-03-20 Abbott Laboratories Nucleic acid primers and probes for detecting tumor cells
EP1228244A4 (en) * 1999-11-04 2005-02-09 California Inst Of Techn METHODS AND DEVICES FOR ANALYZING POLYNUCLEOTIDE SEQUENCES
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのF1t4(VEGFR−3)および抗腫瘍療法
DE60214827T2 (de) 2001-02-12 2007-03-29 Immunivest Corp., Wilmington Kassette als behälter eines probenexemplars für die optische analyse
GB0111324D0 (en) * 2001-05-09 2001-07-04 Unilever Plc Ambient stable beverage
EP1432826B1 (en) 2001-09-24 2012-12-12 Life Technologies Corporation Methods, kits and compositions pertaining to the suppression of detectable probe binding to randomly distributed repeat sequences in genomic nucleic acid
US20030082632A1 (en) 2001-10-25 2003-05-01 Cytoprint, Inc. Assay method and apparatus
KR20040047971A (ko) 2001-10-26 2004-06-05 이뮤니베스트 코포레이션 동일 샘플상에서의 광범위 핵산 및 이의 형태학적 특질에대한 다중 매개변수 분석법
WO2003048378A2 (en) 2001-12-04 2003-06-12 Euregen Llc Methods and compositions for selectively cleaving dna containing duplex acids in a complex nucleic acid mixture
AU2002360741B2 (en) 2001-12-21 2008-07-17 Immunex Corporation Endothelial stem cells, populations, methods of isolation and use thereof
AU2003224978A1 (en) 2002-04-12 2003-10-27 Curators Of The University Of Missouri ECIST microarrays for dual screening of DNA hypermethylation and gene silencing
JP2005524833A (ja) 2002-05-03 2005-08-18 イムニベスト・コーポレイション 分析細胞イメージング用のデバイスおよび方法
US7648678B2 (en) 2002-12-20 2010-01-19 Dako Denmark A/S Method and system for pretreatment of tissue slides
EP1597353B1 (en) 2003-02-27 2010-11-24 Veridex, LLC CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
WO2004081225A2 (en) 2003-03-07 2004-09-23 Rubicon Genomics, Inc. Amplification and analysis of whole genome and whole transcriptome libraries generated by a dna polymerization process
US20050064450A1 (en) 2003-03-13 2005-03-24 Lucas Joe N. Methods of making repetitive sequences removed probes and uses thereof
CA2526493A1 (en) * 2003-05-22 2004-12-02 Theraptosis S.A. Means for preventing and treating cellular death and their biological applications
EP1673611A4 (en) 2003-09-18 2011-11-30 Immunivest Corp PROGRAMMABLE SAMPLE ANALYSIS AND PREPARATION SYSTEM INDEPENDENTLY OF THE OPERATOR
DE102005006237A1 (de) * 2005-02-10 2006-08-24 Henkel Kgaa Verfahren zur Bestimmung von Keimen
EP1722230A3 (en) 2005-04-27 2009-05-27 MPB MelTec Patent- und Beteiligungsgesellschaft mbH Method for detection of a disease-specific combinatorial molecular pattern motif in a tissue sample of a patient's skin
US9127302B2 (en) 2005-09-20 2015-09-08 Janssen Diagnostics, Llc System for the detection and enumeration of suspect target cells in a mixed cell population
WO2008051478A2 (en) * 2006-10-19 2008-05-02 Chemimage Corporation Photobleaching by high power pulses

Also Published As

Publication number Publication date
CN101672779A (zh) 2010-03-17
EP2169387A3 (en) 2011-03-09
IL199798A (en) 2014-08-31
PT2169387E (pt) 2015-06-03
HK1140820A1 (en) 2010-10-22
BR122018015761B8 (pt) 2021-07-27
US9134237B2 (en) 2015-09-15
CA2674187C (en) 2017-09-12
KR20170094523A (ko) 2017-08-18
MX2009008060A (es) 2010-07-01
CN101672779B (zh) 2016-01-06
CA2674187A1 (en) 2010-01-29
BR122018015761B1 (pt) 2019-10-22
JP2010029187A (ja) 2010-02-12
DK2169387T3 (en) 2015-05-26
EP2169387B1 (en) 2015-04-22
ES2542061T3 (es) 2015-07-30
CA2975186A1 (en) 2010-01-29
IL199798A0 (en) 2010-05-17
JP6109464B2 (ja) 2017-04-05
EP2169387A2 (en) 2010-03-31
KR20100012847A (ko) 2010-02-08
BRPI0902559A2 (pt) 2011-04-05
US20090029378A1 (en) 2009-01-29
PL2169387T3 (pl) 2015-09-30
KR101764597B1 (ko) 2017-08-03

Similar Documents

Publication Publication Date Title
EP2169387B1 (en) A high sensivity multiparameter method for rare event analysis in a biological sample
US10613089B2 (en) Method of using non-rare cells to detect rare cells
US20230085158A1 (en) Method of using non-rare cells to detect rare cells
Basiji et al. Cellular image analysis and imaging by flow cytometry
KR101716555B1 (ko) 포유동물 대상체에서 5t4-양성 순환 종양 세포를 검출하는 방법 및 5t4-양성 암을 진단하는 방법
CN108350483A (zh) 在用户定义的切片组织区域中同时定量多种蛋白质
CN108350486A (zh) 在横切面组织的用户定义区域中的基因表达的同时定量
MX2014006884A (es) Aparato, sistema y metodo para identificar celulas tumorales circulantes.
WO2021241757A1 (ja) 情報処理装置、生体試料解析方法、生体試料検出装置、および生体試料検出システム
Hsieh et al. Location and biomarker characterization of circulating tumor cells